8-K: FibroBiologics Faces Nasdaq Delisting Threat

FibroBiologics, Inc. received a second delisting notice from Nasdaq for failing to meet the minimum bid price requirement, prompting plans for an appeal and a reverse stock split proposal.

Summary

• FibroBiologics, Inc. received a second notification from The Nasdaq Stock Market LLC on December 30, 2025, indicating a plan to delist its securities.
• The delisting is due to the company's continued non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
• The company initially received a non-compliance letter on July 1, 2025, and failed to regain compliance by the 180-calendar day deadline of December 29, 2025.
• FibroBiologics plans to timely request a hearing before the Nasdaq Hearings Panel, which will stay any delisting action pending the outcome of the hearing and any granted extension.
• The company has filed definitive proxy materials on December 29, 2025, seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30 shares, to be determined by the board of directors, as a step to regain compliance.

Sentiment

Score: 3

Explanation: The company failed to meet Nasdaq's listing requirements and received a delisting notice, indicating significant operational or market challenges. While management is taking steps to address the issue by requesting a hearing and proposing a reverse stock split, the outcome remains uncertain and carries substantial risk.

Positives

• The company plans to timely request a hearing before the Nasdaq Hearings Panel, which will temporarily stay any delisting action.
• Management is actively evaluating options and has proposed a reverse stock split to stockholders as a definitive step to regain compliance with Nasdaq's listing rules.

Negatives

• Received a second notification from Nasdaq indicating a plan to delist the company's securities.
• Failed to regain compliance with Nasdaq's minimum $1.00 bid price rule by the December 29, 2025 deadline.
• There is no assurance that the company will be granted an extension by the Nasdaq Hearings Panel or that any actions taken will successfully regain compliance.

Risks

• No assurance that the Nasdaq Hearings Panel will grant an extension for the company to regain compliance.
• No assurance that actions taken by the company, such as a reverse stock split, will be successful in regaining compliance with the Nasdaq minimum bid price rule.
• The potential for delisting from The Nasdaq Capital Market, which could negatively impact liquidity and investor confidence.
• General risks associated with forward-looking statements, where actual results could differ materially from expectations.

Future Outlook

The company plans to request a hearing before the Nasdaq Hearings Panel to appeal the delisting decision and intends to actively monitor its common stock's closing bid price. It will evaluate all available options to regain compliance, including seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30 shares. However, there is no assurance that an extension will be granted or that these actions will successfully lead to compliance.

Management Comments

• "The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by the Staff at least pending the outcome of the hearing and the expiration of any extension that may be granted to the Company by the Panel."
• "The Company intends to actively monitor the closing bid price of its common stock and evaluate all available options to regain compliance with the Rule."
• "Although the Company is taking definitive steps to regain compliance with the Rule, there can be no assurance that the Company will be granted an extension to do so or that any actions taken by the Company will be successful in the Companys effort to regain compliance with the Rule."

Industry Context

This event highlights the challenges smaller biotechnology companies can face in maintaining stock exchange listing requirements, particularly the minimum bid price, which can be influenced by market sentiment, clinical trial progress, and overall financial performance within the competitive biotech sector.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to assess against global benchmarks. The issue is a regulatory compliance matter specific to FibroBiologics, Inc.'s stock performance relative to Nasdaq's rules.

Corporate Governance

Legal Proceedings

• The company is engaged in a regulatory process with The Nasdaq Stock Market LLC regarding its non-compliance with listing rules, which could lead to delisting if not resolved.

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the company's continued listing on Nasdaq, potential for reduced liquidity if delisted, and the impact of a reverse stock split on their holdings and perceived value.
• Employees: Potential impact on morale and retention due to the company's precarious listing status and associated market perception.
• Creditors: May view the company's financial stability and creditworthiness with increased scrutiny due to the delisting threat.

Next Steps

• Timely request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• Actively monitor the closing bid price of common stock.
• Evaluate all available options to regain compliance with Nasdaq's listing rules.
• Seek stockholder approval for a reverse stock split at a ratio ranging from 1-for-5 to 1-for-30 shares.

Key Dates

Recommendation

FibroBiologics faces an imminent and severe risk of delisting from Nasdaq due to its failure to maintain the minimum bid price. While management intends to appeal and propose a reverse stock split, the success of these measures is uncertain and explicitly stated as such. Delisting would severely impair liquidity and valuation, making the stock highly speculative. A reverse split, while a potential solution for compliance, often signals underlying operational or financial distress and can lead to further investor skepticism and price erosion. Given the high uncertainty and significant downside risk, a strong sell recommendation is warranted to protect capital.

Keywords

Nasdaq delisting, reverse stock split, FBLG, FibroBiologics, listing compliance, minimum bid price, corporate governance